Background Metabolic syndrome has been associated with psoriasis in cross-sectional studies, but data from prospective studies are sparse. Objectives To examine prospectively whether metabolic syndrome and its components are associated with the risk of incident psoriasis in a large population-based study using objective measurements of cardiovascular disease risk factors. Methods We used data from two consecutive surveys of the HUNT Study, Norway (HUNT2, 1995-1997, and HUNT3, 2006-2008. In total 34 996 women and men aged ≥ 20 years without psoriasis in HUNT2 were followed up in HUNT3, and 374 incident cases of psoriasis were identified. We used Cox regression to estimate the adjusted relative risk (RR) of incident psoriasis with its 95% confidence interval (CI). Results Metabolic syndrome was associated with an RR for psoriasis of 1Á66 (95% CI 1Á30-2Á14). To explore the influence of adiposity on this association, we first excluded waist circumference from the definition of metabolic syndrome (adjusted RR 1Á54, 95% CI 1Á14-2Á07) and then adjusted for body mass index (RR 1Á33, 95% CI 0Á97-1Á81). Analyses of the separate components of metabolic syndrome showed positive associations with risk of psoriasis for waist circumference, triglycerides and high-density lipoprotein (HDL) cholesterol, but not for blood pressure or blood glucose. There was also an increased risk of psoriasis for high total cholesterol. The increased risk associated with high triglycerides, HDL cholesterol and total cholesterol was attenuated after adjusting for body mass index. Conclusions In this large prospective study from a general population, we found that metabolic syndrome was associated with increased risk of incident psoriasis, and our results suggest that this positive association could, at least partly, be attributed to adiposity.
Summary
Background Metabolic syndrome has been associated with psoriasis in cross-sectional studies, but data from prospective studies are sparse. Objectives To examine prospectively whether metabolic syndrome and its components are associated with the risk of incident psoriasis in a large population-based study using objective measurements of cardiovascular disease risk factors. Methods We used data from two consecutive surveys of the HUNT Study, Norway (HUNT2, 1995 -1997 , and HUNT3, 2006 -2008 . In total 34 996 women and men aged ≥ 20 years without psoriasis in HUNT2 were followed up in HUNT3, and 374 incident cases of psoriasis were identified. We used Cox regression to estimate the adjusted relative risk (RR) of incident psoriasis with its 95% confidence interval (CI). Results Metabolic syndrome was associated with an RR for psoriasis of 1Á66 (95% CI 1Á30-2Á14). To explore the influence of adiposity on this association, we first excluded waist circumference from the definition of metabolic syndrome (adjusted RR 1Á54, 95% CI 1Á14-2Á07) and then adjusted for body mass index (RR 1Á33, 95% CI 0Á97-1Á81). Analyses of the separate components of metabolic syndrome showed positive associations with risk of psoriasis for waist circumference, triglycerides and high-density lipoprotein (HDL) cholesterol, but not for blood pressure or blood glucose. There was also an increased risk of psoriasis for high total cholesterol. The increased risk associated with high triglycerides, HDL cholesterol and total cholesterol was attenuated after adjusting for body mass index. Conclusions In this large prospective study from a general population, we found that metabolic syndrome was associated with increased risk of incident psoriasis, and our results suggest that this positive association could, at least partly, be attributed to adiposity.
What's already known about this topic?
• Metabolic syndrome has been associated with psoriasis in cross-sectional studies, but data from prospective studies are limited.
What does this study add?
• Metabolic syndrome was associated with increased risk of incident psoriasis.
• A substantial part of this association seems to be attributable to adiposity.
Psoriasis is a common chronic skin disease, with systemic inflammation recognized as being central in the pathogenesis. 1 Psoriasis has been associated with cardiovascular disease and cardiovascular disease risk factors in several studies, both cross-sectionally and in prospective studies investigating whether psoriasis increases the risk of these comorbidities. [2] [3] [4] [5] It has therefore been hypothesized that the systemic inflammation in psoriasis leads to insulin resistance, endothelial dysfunction and subsequently atherosclerosis and myocardial infarction. 6 However, the temporality in these associations is still debated, [7] [8] [9] and few studies have investigated whether cardiovascular disease risk factors could increase the risk of developing psoriasis. It has been shown that patients with psoriasis are on average more obese than controls, 10 and that weight loss can lead to remission of psoriasis or reduction of psoriasis severity.
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We have recently shown that obesity, high waist circumference and weight gain substantially increase the risk of developing psoriasis. 15 In addition, prospective studies have found that hypertension and hypercholesterolaemia are associated with increased risk of incident psoriasis. 16, 17 It could therefore be speculated that a clustering of these cardiovascular disease risk factors is associated with a particularly high risk of psoriasis. Metabolic syndrome is a constellation of abdominal obesity, atherogenic dyslipidaemia, raised blood pressure and insulin resistance, and is associated with a substantially increased risk of cardiovascular disease. 18 Most studies of psoriasis and metabolic syndrome are cross-sectional, 3, [19] [20] [21] [22] [23] but one study reported that people with diabetes, hypertension or dyslipidaemia had increased risk of psoriasis. 24 To our knowledge, no previous study has prospectively examined the association between metabolic syndrome and the risk of incident psoriasis. We used data from a large population-based study with objective measurements of cardiovascular disease risk factors to examine prospectively whether metabolic syndrome was associated with increased risk of incident psoriasis. In addition, we investigated the association between the different factors constituting metabolic syndrome and psoriasis risk.
Patients and methods

Data source
All inhabitants in the county of Nord-Trøndelag, Norway, aged ≥ 20 years have been invited to the Nord-Trøndelag Health Study (HUNT) in three different surveys so far. For the present study, we used data from HUNT2 (1995) (1996) (1997) , where 93 898 individuals were invited and 65 237 (69%) participated; and HUNT3 (2006) (2007) (2008) , where 93 860 individuals were invited and 50 807 (54%) participated. 25 Information on health-and lifestyle-related factors was obtained by questionnaires. Furthermore, at a clinical examination, standardized measurements of blood pressure, height, weight and waist circumference were collected, and a nonfasting blood sample was taken. More details can be found at http://www.ntnu.edu/hunt.
Study population
We selected all 36 968 individuals who had participated in both the HUNT2 and HUNT3 surveys. We excluded five individuals with missing data on the psoriasis question in HUNT3, 676 with missing data on age at psoriasis onset, 123 with missing information on height or weight and 1168 with a psoriasis diagnosis at baseline in HUNT 2. This left 34 996 individuals for statistical analyses. Because of missing information on different exposure variables, the number of individuals in each analysis varied from 34 610 (metabolic syndrome) to 34 953 (total cholesterol and triglycerides).
Psoriasis diagnosis
We obtained information on psoriasis from HUNT3, where one of the questions was 'do you have or have you had any of the following?', with 'psoriasis (yes, no)' as one of the response options. Those who answered 'yes' were asked about their age at psoriasis onset. This information was used to calculate the follow-up time from participation in HUNT2 until onset of psoriasis between HUNT2 and HUNT3, and to exclude people with psoriasis at baseline, as no psoriasis data were available for HUNT2.
Metabolic factors
We defined metabolic syndrome using modified National Cholesterol Education Program Expert Panel-Adult Treatment Panel III criteria, 26 where at least three of the following criteria had to be fulfilled for a patient to be classified as having metabolic syndrome: (i) waist circumference > 102 cm for men and
for men and < 1Á3 mmol L À1 for women, (iv) blood pressure ≥ 130 mmHg systolic or ≥ 85 mmHg diastolic or self-reported treatment for elevated blood pressure and (v) blood glucose ≥ 11Á1 mmol L À1 or answering yes to the question 'have you had or do you have diabetes?'. This cut-off level for blood glucose was set because the blood sample was collected nonfasting. The same cut-off has previously been used in other studies, 27, 28 and was also used as a positive screen in the HUNT study. In addition, we divided blood pressure into three categories: systolic blood pressure < 120, 120-139 or ≥ 140 mmHg and diastolic blood pressure < 80, 80-89 or ≥ 90 mmHg. 29 We also used information on total cholesterol, which was dichotomized into ≤ 6 or > 6 mmol L À1 .
At a clinical examination, specially trained nurses or technicians measured blood pressure and recorded body height and weight with the participants wearing light clothes and no shoes. 30 Height was measured to the nearest centimetre and weight to the nearest half kilogram. Waist circumference was measured to the nearest centimetre at the level of the umbilicus with a steel band. Blood pressure was measured with a Critikon Dinamap 845XT (GE Healthcare, Little Chalfont, U.K.) based on oscillometry, and the mean of the second and third readings was reported. Blood samples were analysed at the Central Laboratory at Levanger Hospital, on a Hitachi 911 Analyzer (Hitachi, Mito, Japan), using reagents from Boehringer Mannheim (Mannheim, Germany), and time since the last meal was recorded. Glucose was measured by an enzymatic hexokinase method, and total cholesterol, HDL cholesterol and triglycerides were measured using enzymatic colorimetric methods.
Statistical analysis
We used Cox regression to calculate hazard ratios as estimates of relative risk (RR) for incident psoriasis between categories of metabolic syndrome (yes or no) and the number of metabolic factors. We also estimated the RR of psoriasis associated with the separate components of metabolic syndrome, both as categorical variables and as continuous measures using SD scores (z-score). The precision of all estimated associations was assessed by 95% confidence intervals (CIs).
Based on a priori knowledge we adjusted all associations for possible confounding by age (years), sex, education (< 10 years, 10-12 years, ≥ 13 years and unknown; n = 802) and smoking (never, former, current and unknown; n = 294). We also assessed possible confounding by body mass index (BMI) using various forms of the variable: continuous (kg m À2 ), categorical (< 18Á5, 18Á5-24Á9, 25Á0-29Á9 or ≥ 30Á0 kg m À2 ) and by linear splines with knots at 20, 25 and 30 kg m À2 . 31 To be able to adjust for BMI in the analyses of metabolic syndrome, we did calculations where we excluded waist circumference from the definition of metabolic syndrome, and thus three out of four factors were required for the patient to be defined as having metabolic syndrome. As we were uncertain whether BMI would cover all aspects of adiposity, we also adjusted for waist circumference.
In supplementary analyses, we further stratified metabolic syndrome by sex and age groups. Statistical interaction by sex and age groups was evaluated in a likelihood ratio test by constructing product terms between the exposure variables and sex/age. We also conducted a set of sensitivity analyses to explore the robustness of our results. Firstly, because blood samples were collected in a nonfasting state, we excluded 15 096 individuals who reported that they had eaten during the last 2 h before blood sampling and 136 with missing information on time since last meal from the analyses of blood lipids and blood glucose. Secondly, the analyses of blood pressure were repeated after excluding 3440 individuals on antihypertensive medication and 66 with missing information on this variable, and then after adding 10 mmHg to systolic pressure and 5 mmHg to diastolic pressure in those who reported using antihypertensive medication. Thirdly, to limit possible bias due to measurement error of age at diagnosis or due to existing undiagnosed disease at baseline, we excluded cases of psoriasis with disease onset during the first year after baseline. Finally, we repeated all analyses in a complete-case strategy excluding individuals with missing data on education and smoking.
We evaluated departure from the proportional hazards assumption by tests of Schoenfeld residuals and graphical inspection of log-log plots. The analyses were performed using Stata for Windows (version IC 14.1; StataCorp, College Station, TX, U.S.A.).
Ethics
Participation in the HUNT study was based on written informed consent, and our study was approved by the
Results
In total, 34 996 participants were included in the study; 19 347 (55Á3%) were women and 15 649 (44Á7%) men. Of these, 374 (1Á1%) developed psoriasis during follow-up: 189 women and 185 men. The mean age for the whole study population was 47Á0 years, and the mean BMI was 26Á1 kg m À2 (Table 1) . There was no evidence of departure from the proportional hazards assumption for the results presented below.
Metabolic syndrome was associated with increased risk of psoriasis, with an RR of 1Á66 (95% CI 1Á30-2Á14) (Table S1 ; see Supporting Information). When we excluded waist circumference from the definition, metabolic syndrome was associated with an RR of 1Á54 (95% CI 1Á14-2Á07), and after adjustment for BMI this was attenuated to 1Á33 (95% CI 0Á97-1Á81). There was a positive association between the number of metabolic factors and risk of psoriasis, but the increased risk was confined largely to those with three or more metabolic factors. The positive association remained after excluding waist circumference as one of the metabolic factors, but was attenuated after adjusting for BMI.
In additional analyses stratified by sex, we found a higher RR of psoriasis among men with metabolic syndrome than among women (Table S2 ; see Supporting Information). However, this difference disappeared after excluding waist circumference and adjusting for BMI. When stratifying by age groups, we found a higher RR of psoriasis among 19-34Á9 year olds with metabolic syndrome than among 35-90 year olds (Table S3 ; see Supporting Information). There was no evidence of statistical interaction by sex or age (all P-values > 0Á23). Table S4 (see Supporting Information) shows associations for the different components of metabolic syndrome. We found an RR of psoriasis of 1Á68 (95% CI 1Á30-2Á17) in individuals with high waist circumference, and a positive association with risk of psoriasis for high triglycerides, which was attenuated after adjusting for BMI (Table S4 ). Additionally, we had information about nonfasting total cholesterol, which is not included in metabolic syndrome, and a total cholesterol > 6 mmol L À1 gave an RR of psoriasis of 1Á26 (95% CI 1Á01-1Á57) after BMI adjustment. Sensitivity analyses excluding individuals with onset of psoriasis in the first year after baseline (n = 40) gave unchanged results for all analyses (data not shown). Additional adjustments for waist circumference did not alter the estimates, nor did adjustment for BMI in categories or in splines. Excluding those who had eaten in the last 2 h before blood sampling or with missing information on time since last meal attenuated the estimate for total cholesterol to 1Á18 (95% CI 0Á88-1Á58), whereas for the other lipids and blood glucose the results remained unchanged. In addition, excluding individuals on blood pressure medication and adding 10 mmHg and 5 mmHg to the continuous variables of systolic and diastolic blood pressure for the analyses of blood pressure did not alter the estimates. Finally, complete-case analyses gave unchanged results.
Discussion
In this large population-based study with up to 13 years of follow-up, we found metabolic syndrome to be associated with an increased RR of incident psoriasis. The risk diminished when controlling for adiposity, suggesting that this is the most important driver in this association. This was also confirmed by the weak associations between psoriasis and the factors constituting metabolic syndrome except for raised waist circumference. However, we did find a dose-response relationship between the number of metabolic factors and risk of psoriasis, and although the association became weaker, this relationship remained after excluding waist circumference and adjusting for BMI.
Few studies have prospectively investigated the risk of incident psoriasis in relation to metabolic syndrome or its components. A study from Korea found that individuals who were metabolically unhealthy (defined by the presence of at least one of the following: diabetes mellitus, hypertension or hyperlipidaemia), but not obese, had a 30% increased risk of psoriasis. Approximately the same risk was found for metabolically unhealthy obese individuals, both groups compared with metabolically healthy nonobese. 24 The authors' conclusion that metabolic health status is associated with increased risk of incident psoriasis regardless of obesity is in contrast with our findings. Previous large cohort studies have identified obesity as a risk factor for psoriasis, 15,32-34 but to our knowledge there are no former studies of metabolic syndrome and risk of incident psoriasis in a Western population.
In contrast to our finding of no association between hypertension and incident psoriasis, a U.S. study of women found 20% increased risk of psoriasis in participants with a selfreported history of physician-diagnosed hypertension. The risk was highest among those with hypertension lasting ≥ 6 years, with 30% increased risk. 16 In another study from the U.S.A., the risk of psoriasis was 26% in women with hypercholesterolaemia, 17 which is the same point estimate as ours. The investigators used self-reported history of physicians' diagnosis, while we used measured cholesterol level. In contrast to these findings, a prospective cohort study with a nested case-control design using data from the General Practice Database in the U.K. 35 found no increased risk of psoriasis in relation to diagnosis of diabetes, hypertension or hyperlipidaemia. We found no increased risk of psoriasis for the components of metabolic syndrome other than waist circumference. However, metabolic syndrome was still associated with an increased relative risk of psoriasis after controlling for adiposity, which we hypothesize could be caused by the combined effect of the risk factors.
A major strength of this study is the population-based design including a large number of both women and men. The prospective design with a relatively long follow-up enables us to infer the direction of the examined association. In addition, we had information on objectively measured anthropometric values, blood pressure and blood samples, which reduces possible bias due to misclassification. Our comprehensive data enabled us to adjust for several possible confounders, but residual confounding due to poorly measured or unmeasured factors cannot be ruled out. The extensive adjustment for BMI in different models limits possible residual confounding that could be caused by nonlinear associations.
There are some limitations of our study. One is the use of self-reported psoriasis; however, a recent validation study from our research group found a positive predictive value of 78% of the psoriasis question in HUNT3, 36 which indicated that this is a valid measure of psoriasis in this cohort. Nevertheless, we had to rely on self-reported year of diagnosis to be able to identify new cases of psoriasis after baseline. Selfreported age at onset of disease has hardly been validated, but reported age at onset of asthma has been found to have high reliability. [37] [38] [39] Whether this is also true for psoriasis onset is not clear. Some participants reporting psoriasis onset just after baseline could potentially be false incident cases, but excluding those who reported onset during the first year of followup did not change the results. It could be speculated that an unfavourable lifestyle and a clustering of risk factors could lead to more severe disease, but our data did not contain information of severity of psoriasis for the cases that occurred during follow-up. Moreover, as the participants of our study were aged ≥ 20 years, it is likely that individuals with earlyonset psoriasis are under-represented in our cohort. Another limitation of our study is the nonfasting state of the blood sampling. However, while glucose and triglycerides are known to be sensitive to food intake, HDL and total cholesterol are less influenced. 40, 41 Sensitivity analyses excluding individuals who had eaten in the last 2 h did not change the results for triglycerides and HDL cholesterol, but lack of information on lipid-lowering drugs could potentially also have influenced the results. As we did not have information on fasting glucose, we chose to include existing diabetes as a marker of insulin resistance. Although we could not distinguish between type 1 and type 2 diabetes, about 80-90% of patients with diabetes are estimated to have type 2 diabetes, which is characterized by insulin resistance. 42, 43 The information on exposure variables was not updated throughout the follow-up period, and could thus be subject to misclassification due to changes over time.
There are different definitions of metabolic syndrome, some with lower cut-off values for waist circumference than we have used in the present study. 44 Using a lower cut-off would define more participants as cases, which could lead to cases that were clinically less relevant. Participants needed to have attended both HUNT2 and HUNT3 to be included in this study, which introduces the possibility of selection bias. Individuals with metabolic syndrome are likely to have had increased morbidity and mortality between the surveys, and could hence be less likely to participate at follow-up, which would lead to an underestimation of the association between metabolic syndrome and psoriasis. One study from HUNT found that nonparticipants were older with lower socioeconomic status and higher morbidity and mortality than participants. 45 It is unclear whether psoriasis leads to conditions such as obesity, hyperlipidaemia and metabolic syndrome, or whether these conditions influence the pathogenesis of psoriasis. 8, 9, 17, 46 Our study supports the latter theory, that metabolic syndrome, increased waist circumference and high total cholesterol could have a role in the risk of incident psoriasis. Metabolic syndrome and psoriasis have common inflammatory pathways such as chronic T helper-1 and -17-mediated inflammation. 46, 47 Many cytokines are also found to be common in both psoriasis pathogenesis and lipoprotein dysregulation. 48 In addition, adipose tissue produces adipokines, which are drivers of chronic inflammation. 9, 49 Furthermore, one study found shared genes between psoriasis and dyslipidaemia, hypertension and increased coronary artery disease, 50 while others have found no genetic association between psoriasis and metabolic syndrome or coronary artery disease. [51] [52] [53] In conclusion, in this large population-based prospective study, we found that metabolic syndrome is associated with increased risk of incident psoriasis, and our results show that adiposity is a central factor in this association. In agreement with this, analyses of the separate components of metabolic syndrome showed the strongest association between waist circumference and risk of psoriasis. From a public health perspective, maintaining a normal body weight and avoiding clustering of cardiovascular risk factors could contribute to the prevention of psoriasis.
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